NDA 018564 · Otsuka Icu Medcl
Dextrose 20% In Plastic Container
Dextrose · Injection
Last checked: Nov 19, 2026Latest source record: May 14, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Mar 23, 1982
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3,797
712 Phase 3, 359 recruiting
FAERS reports
13,727
12,671 serious, 2,102 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 2, 2025.
Dextrose Injection 20%, 30%, 40%, 50% and 70%, mixed with amino acids or other compatible intravenous fluids, is indicated as a source of calories for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. Dextrose Injection 20%, 30%, 40%, 50% and 70%, mixed with amino acids or other compatible intravenous fluids, is indicated as a source of calories for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient or contraindicated ( 1 )
Mechanism: Dextrose Injection is used to supplement nutrition by providing glucose parenterally. Dextrose is oxidized to carbon dioxide and water, yielding energy.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 23, 1982 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- DEXTROSE 20% IN PLASTIC CONTAINER · DEXTROSE 20GM/100ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dextrose" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Study of Vitamin D and Omega-3 Supplementation for Preventing DiabetesPivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT01633177 · 22,220 participants · Start Nov 2011 · Primary completion May 30, 2024
Drug: Omega-3 fatty acid (fish oil); Fish oil placebo · For: Type 2 Diabetes
Sites: Boston, Massachusetts
- High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention ProgramPivotal-lookingStatus unknown
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT05782881 · 16,000 participants (planned) · Start Jan 15, 2023 · Primary completion Dec 31, 2023
Drug: Statin · For: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Coronary Disease
Sites: Enshi, China; Ezhou, China; Huanggang, China · 107 sites in all
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04255433 · 13,299 participants · Start May 29, 2020 · Primary completion Jun 12, 2025
Drug: Tirzepatide; Dulaglutide · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Concord, California; Covina, California · 635 sites in all
- The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00069784 · 12,537 participants · Start Aug 2003 · Primary completion Dec 2011
Drug: insulin glargine (HOE901); omega-3 polyunsaturated fatty acids (PUFA) and 1 more · For: Diabetes Mellitus, Non-Insulin-Dependent
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Cove, Australia · 40 sites in all
- Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 DiabetesPivotal-lookingCompleted
The George InstituteAcademic, hospital or other
NCT00145925 · 11,140 participants · Start Jun 2001 · Primary completion Mar 2008
Drug: Perindopril-indapamide; Gliclazide MR-based glucose lowering · For: Diabetes Mellitus, Type 2
Sites: Melbourne, Australia; Montreal, Canada; Beijing, China · 5 sites in all
- 18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed TomographyPivotal-lookingNot yet recruiting
Eastern Health, CanadaAcademic, hospital or other
NCT04615156 · 10,000 participants (planned) · Start Nov 1, 2020 · Primary completion Nov 1, 2027
Drug: 18F-2-fluoro-2-deoxy-D-glucose · For: Solitary Pulmonary Nodule; Oncology; 18F-2-fluoro-2-deoxy-D-glucose and 1 more
- Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes MellitusPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02465515 · 9,463 participants · Start Jul 1, 2015 · Primary completion Feb 20, 2018
Drug: Albiglutide 30 mg; Albiglutide 50 mg and 1 more · For: Diabetes Mellitus
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 607 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myelosuppression1,855
- off label use1,091
- nausea1,037
- drug ineffective973
- vomiting963
- acute kidney injury807
- pyrexia731
- white blood cell count decreased714
- dyspnoea683
- sepsis588
- abdominal pain544
- hypotension532
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 53 |
| 2005 | 36 |
| 2006 | 49 |
| 2007 | 40 |
| 2008 | 64 |
| 2009 | 83 |
| 2010 | 117 |
| 2011 | 145 |
| 2012 | 148 |
| 2013 | 128 |
| 2014 | 395 |
| 2015 | 199 |
| 2016 | 312 |
| 2017 | 284 |
| 2018 | 380 |
| 2019 | 487 |
| 2020 | 611 |
| 2021 | 962 |
| 2022 | 1,571 |
| 2023 | 2,020 |
| 2024 | 1,949 |
| 2025 | 1,980 |
| 2026 | 1,712 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Conservative Treatments of Carpal Tunnel Syndrome: A Systematic Review and Network Meta-analysis.
Chen Y, Han B, Zhang X, et al. · Arch Phys Med Rehabil 2025 · Systematic Review, Network Meta-Analysis
- Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial.
Fowler AA, Truwit JD, Hite RD, et al. · JAMA 2019 · Multicenter Study, Randomized Controlled Trial
- Efficacy of 10%,25% and 50% dextrose in the treatment of hypoglycemia in the emergency department - A randomized controlled study.
Verma A, Jaiswal S, Reid C, et al. · Am J Emerg Med 2024 · Randomized Controlled Trial
- Perioperative Dextrose Infusion and Postoperative Nausea and Vomiting: A Meta-analysis of Randomized Trials.
Zorrilla-Vaca A, Marmolejo-Posso D, Stone A, et al. · Anesth Analg 2019 · Meta-Analysis, Systematic Review
- Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.
Lee WM, Hynan LS, Rossaro L, et al. · Gastroenterology 2009 · Multicenter Study, Randomized Controlled Trial
- Variations in Neuromuscular Functions After Platelet-Rich Plasma and Dextrose Injections in Chronic Lateral Epicondylitis: A Randomized Controlled Study.
Chen Y, Hong CK, Hsu KL, et al. · Sports Health 2025 · Randomized Controlled Trial
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.